外泌体为动脉粥样硬化提供新的干预靶点

发布时间：2018-03-15 03:04

  本文选题：外泌体　切入点：动脉粥样硬化　出处：《中国动脉硬化杂志》2017年04期 　论文类型：期刊论文

【摘要】：动脉粥样硬化是一种慢性炎症性疾病。临床上使用的抗动脉粥样硬化药物的目标主要集中在减少循环低密度脂蛋白水平,升高高密度脂蛋白水平,并减轻炎症。然而,心血管疾病的发病率和死亡率仍然很高。因此,识别未知的治疗靶点和开发新的抗动脉粥样硬化药物的需求越来越大。外泌体是活细胞分泌的来源于晚期核内体(也称为多囊泡体)的膜性囊泡。外泌体内含有与来源细胞相关的蛋白质、rRNA和微小RNA,并能够通过生物屏障,从而发挥各种生物学功能。外泌体有望成为一种治疗动脉粥样硬化的新型给药途径及基因治疗载体。
[Abstract]:Atherosclerosis is a chronic inflammatory disease. Antiatherosclerosis drugs used clinically focus on reducing circulating low density lipoprotein levels, raising high density lipoprotein levels, and reducing inflammation. The morbidity and mortality of cardiovascular diseases are still very high. The need to identify unknown therapeutic targets and to develop new anti-atherosclerotic drugs is growing. Exocrine is a membranous vesicle secreted by living cells from late nuclear intranuclear bodies (also known as polycystic bodies). Exocrine bodies contain. Proteins associated with the source cells, rRNA and small RNAs, can pass through biological barriers, The exocrine may become a novel drug delivery pathway and gene therapy carrier for atherosclerosis.
【作者单位】： 南华大学心血管疾病研究所动脉硬化学湖南省重点实验室;
【基金】：国家自然科学基金项目(81270360) 湖南省科技计划重点项目(2014FJ2012)
【分类号】：R543.5
，

本文编号：1614123